Future-proofing Bioanalysis - Contributing to a sustainable world
The meeting will be organised simultaneously in
different regions on 24 and 25 September 2020 combined with a live streaming
– see TRAVEL AND LOCATION for more information
Program
The 6th YSS will be organised simultaneously at different sites in different regions, covering all regions which young scientists could reasonably reach by train/car/local travel. The regions we identified are: UK-North, UK-Mid/South, Benelux, Italy, Switzerland/South-Germany, Rest-of-Germany, Denmark/Sweden and Spain/South of France. This spread should facilitate young scientists to travel locally to the meeting and still benefit from face to face interactions as good and safe as possible. We keep our fingers crossed that young scientists from other regions could still be allowed to travel to one of above regions. Alternatively, they could join (part of) the meeting via live streaming.
Agenda, version 28 May 2020 – all times are CET (Brussels time zone)
| 24 September 2020 | |||
| 11:30 | 13:00 | If local site can host 2 days: a local welcome | |
| 13:00 | 13:15 | Welcome – coming online | |
| 13:15 | 14:00 | Session 1: Is non-standard the new standard? | |
| 13:15 | 13:30 | Connor Walker (Arcinova) | |
| Non-standard technique in a regulated environment: what considerations come with it? | |||
| 13:30 | 13:45 | Salvatore Calogero (Swiss BioQuant) | |
| FACS in the bioanalysis | |||
| 13:45 | 14:00 | Eugenia Hoffmann (F. Hoffmann-La Roche) | |
| Impact of drug/anti-drug antibody complexes on drug pharmacokinetics: advanced bioanalysis for a better understanding of immunogenicity | |||
| Parallel session | |||
| 14:30 | 15:45 | Parallel Session 2: Rethinking Matrix | |
| 14:30 | 14:45 | Michele Protti (Unibo) | |
| Unraveling details and potentials of VAMS technique: towards the raise of a new golden standard | |||
| 14:45 | 15:00 | Camilla Marasca (Unibo) | |
| Novel microfluidic-based sampling for therapeutic drug monitoring of patients under treatment with the antidepressant drug vortioxetine | |||
| 15:00 | 15:15 | Virginia Brighenti (University of Modena and Reggio Emilia) | |
| New Analytical Tools for the Study of Bioactive Polyphenols in Prunus avium L. (sweet cherry) and Evaluation of their Anti-oxidant Activity on an In vivo Model. | |||
| 15:15 | 15:30 | Maaike Bruin (The Netherlands Cancer Institute (NKI)) | |
| Development and validation of an LC-MS/MS method with a broad linear dynamic range utilizing natural isotopologue transitions for quantification of tivozanib | |||
| 15:30 | 15:45 | Jana Verstraete (UGent) | |
| The simultaneous quantification of thiamine, its phosphate derivatives and precursors in Arabidopsis thaliana: validation and application. | |||
| 14:30 | 15:45 | Parallel Session 3: ADApting | |
| 14:30 | 14:45 | Hannah Craig (Covance) | |
| Biosimilar ADA assessments using the Gyrolab platform | |||
| 14:45 | 15:00 | Fanni Suomi (Syrinx Bioanalytics) | |
| Concentration analysis and immunogenicity testing of next generation oligonucleotides and targeted delivery molecules | |||
| 15:00 | 15:15 | Cara Gunning (Charles River Laboratories) | |
| Approaches to Improve Drug Tolerance in Immunogenicity Assays | |||
| 15:15 | 15:30 | Zoe Whiffen (LGC) | |
| Anti-PEG: past, present and future difficulties in a regulated environment | |||
| 15:30 | 15:45 | Adam Williams (AstraZeneca) | |
| Development of a method for detection of anti-drug antibodies against the PEG component of a lipid nanoparticle drug product | |||
| 16:30 | 17:30 | Session 4: Before we digest….let’s digest. | |
| 16:30 | 16:45 | Bas Sleumer (PRA Health Sciences) | |
| The differences between digested and intact protein analysis: determination of somatropin in rat plasma. | |||
| 16:45 | 17:00 | Lisa Delahaye (UGent) | |
| Determination of paracetamol-albumin adducts via LC-HRMS | |||
| 17:00 | 17:15 | Matthew Franklin (Thermo Fisher Scientific) | |
| Changing up protein digestion during sample preparation to improve protein quantitation from the very beginning | |||
| 17:15 | 17:30 | Terence Hetzel (Bayer) | |
| Determination of thorium-conjugated monoclonal antibody from monkey plasma by different LC-MS technologies | |||
| 17:30 | for those staying overnight – enjoy the evening whilst keeping social distance | ||
| 25 September 2020 | |||
| 09:00 | 10:30 | Site dependent local activities | |
| 10:30 | 12:00 | Science Café: A Sustainable Future | |
| Format: round table | |||
| During this session we want to engage you how we can contribute to a sustainable future. | |||
| This includes e.g. stimulating or applying the 3Rs (Replacement, Reduction and Refinement) and/or the principles of green lab/chemistry… | |||
| We are preparing a dynamic round table discussion where all of you can contribute. | |||
| 12:30 | 13:30 | Interactive poster viewing | |
| 13:45 | 14:15 | Pleanra Feedback from local Science Café round tables: A Sustainable Future | |
| 14:30 | 15:45 | Session 5: It’s what’s inside that counts | |
| 14:30 | 14:45 | Coral Munday (LGC) | |
| Fit-for-Purpose Validation: A Non-Standard Approach for a Non-Standard Biomarker Assay | |||
| 14:45 | 15:00 | Mondanelli Giada (University of Perugia) | |
| Indoleamine 2,3-dioxygenase 2 as new biomarker of tumor progression | |||
| 15:00 | 15:15 | Malleswari Challagundla (AbbVie) | |
| Development and validation of alpha-synuclein aggregation assay using surrogate matrix | |||
| 15:15 | 15:30 | Tessa McDonald (Unilabs York Bioanalytical Solutions) | |
| Qualifying the measurement of endogenous and synthetic spiked pharmacodynamic biomarker in matrix, in the presence of drug | |||
| 16:00 | 17:15 | Session 6: Compete to Collaborate! | |
| 16:00 | 16:15 | Rebecca Taylor (Covance) | |
| Investigating generic PK methods of quantifying human monoclonal antibodies in pre-clinical species by LC-MS and ligand-binding assays. | |||
| 16:15 | 16:30 | Chris Williams (QPS Netherlands) | |
| Hybrid LC-MS ligand binding assays for bioanalysis | |||
| 16:30 | 16:45 | Rebecca Paterson (Charles River Laboratories) | |
| Antibody Drug Conjugate Bioanalysis – An opportunity for LBA and LC-MS Synergy? | |||
| 16:45 | 17:00 | Closing Remarks and Adjourn | |
Copyright 2019 EBF
EBF vzw is the registered non-profit organisation of the European Bioanalysis Forum
Read more about EBF at our community site: www.e-b-f.eu